Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 7, 2005, Pages 414-419

  Almeida, Susana ^a,b   Filipe, Augusto ^a   Almeida, Ana ^a   Wong, Hon ^c   Caparrós, Natalia ^d   Tanguay, Mario ^c  

^a Tecnimede Group   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c SFBC Anapharm   (Canada)

^d Anapharm Europe   (Spain)

Author keywords

CAS 100986 85 4; Levofloxacin, bioavailability, bioequivalence; Pharmacokinetics, sex difference

Indexed keywords

LEVOFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SEX; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION;

EID: 22544467452     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296880     Document Type: Article

References (7)

1. Wimer, S. M., Schoonover, L., Garrison, M. W., Levofloxacin: a therapeutic review. Clin. Ther. 20, 1049 (1998)
2. Chien, S. C., Chow, A. T., Natarajan, J. et al., Double-blind evaluation of the safety and pharmacokinetics of multiple oral once daily 750-miligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 42, 885 (1998)
3. Chen, M. L., Lee, S. C., Ng, M. J. et al., Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin. Pharmacol. Ther. 68, 510 (2000)
4. Chien, S. C., Chow, A. T., Nararajan, J. et al., Absence of age and gender effects on the pharmacokinetics of a single 500-mg oral dose of levofloxacin in healthy subjects. Antimicrob. Agents Chemother. 41, 1562 (1997)
5. International Conference on Harmonisation, Good Clinical Practice Consolidated Guideline, E6 (1996)
6. CPMP (Committee for Proprietary Medicinal Products), Note For Guidance on the Investigation of Bioavailability and Bioequivalence (2001)
7. CDER-FDA, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations, October 2000